Here’s what Aixial do to tackle the feasibility challenges in rare disease clinical trials. Rare disease trials require access-focused strategies

Effective aggregate safety reporting is a cornerstone of patient safety, regulatory compliance, and informed decision-making.

Check out our poster to dive deeper into the study, understand the methodology, and see the results firsthand.

This article outlines Aixial’s comprehensive best practices for operational oversight of safety system lifecycle management.

At Aixial, we conducted up to 150 neurological studies, up to 300 oncology trials in various geographical areas such as Europe, North America, Asia Pacific, thus giving us the opportunity to oversee what works and what doesn’t work in this field.

With deep therapeutic expertise, cross-regional capabilities, and proven operational performance, Aixial is the CRO partner of choice for biotech and pharma sponsors launching complex early phase programs.

Sarcomas are a diverse and rare group of malignant tumors arising from mesenchymal tissues, including bone, muscle, fat, and connective tissue.

Q&A with Aixial’s experts at ASCO 2025. Learn how we can drive success in complex oncology trials. Find us at Booth #27150.

On April 11, World Parkinson’s Day, we are reminded of the importance of research in improving treatments and finding a cure.

In the European Union, a rare disease is defined as one affecting fewer than 5 out of 10,000 members of the general population…